The Effect of the CO-OP Approach for Children With Cerebral Palsy
Launched by ZEYNEP KOLİT · Mar 12, 2020
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 22 (IBM SPSS Statistics; IBM Corporation, Armonk, NY). One sample Kolmogorov-Smirnov Test was used evaluate the distribution of variables prior to test selection. Group characteristics and outcome measures are described using mean and standard deviations for continuous variables and frequencies and proportions for categorical variables. Descriptive statistics were presented as median for the non-normally distributed quantitative and ordinal data and number (percentage) for the categorica...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • being between 5-12 years of age
- • being diagnosed with CP
- • being at level I, II, or III according to the Gross Motor Function Classification Scale (GMFCS)
- • being at level I, or II according to the Manual Ability Classification System (MACS)
- • having experienced motor performance problems in daily activities, as reported by parents and/or children during interview; have sufficient language ability to communicate with and be understood during treatment.
- Exclusion Criteria:
- • receiving another treatment other than NDT
- • being diagnosed with mental retardation
- • having serious visual or hearing problems.
About Zeynep Koli̇t
Zeynep Kolit is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a commitment to rigorous scientific standards and ethical practices, Zeynep Kolit collaborates with leading healthcare professionals and institutions to conduct comprehensive clinical trials. The organization aims to address unmet medical needs by exploring novel treatment options across various therapeutic areas, ensuring that patient safety and data integrity remain at the forefront of its mission. Through its strategic partnerships and expertise, Zeynep Kolit is poised to contribute significantly to the evolving landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Sıhhiye, Turkey
Patients applied
Trial Officials
Zeynep Kolit, MSc
Principal Investigator
Hacettepe University
Gamze Ekici Çağlar, PhD
Study Director
Hacettepe University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials